Docoh
Loading...

87 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
evidence that the clinical benefits of the drug and its approval outweighs the risks associated with the drug or the present standard of care (e.g
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Sales Agent … on the other. The relative benefits received by the Company on the one hand and the Sales Agent on the other hand shall be deemed to be in the same
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
the economic benefits of the intangible assets are consumed or used up are reliably determinable. The useful life is the best estimate of the period over … drug tax credit and certain other minor temporary differences since it is more-likely-than-not that such benefits will not be realized. The valuation
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
which Processa and its Affiliates and applicable Sublicensees shall use Commercially Reasonable Efforts to provide Ocuphire with the benefits … Party’s employees or for any employee compensation or benefits of the other Party’s employees. No employee or representative of a Party shall have any
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts
10-Q
xfg50ek
13 May 21
Quarterly report
4:30pm
DEF 14A
odrqo9ii
22 Apr 21
Definitive proxy
2:00pm
10-K/A
sak9rc9mxe
7 Apr 21
Annual report (amended)
4:23pm
10-K
eheipkv22lg
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
3ig7d
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
huun11pp1 gelxtzw7n
12 Nov 20
Quarterly report
4:01pm
8-K
718jba6979ow g4iog
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-10.1
i2p2pqduflmjiykh1
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-1.1
8a9ym
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
ozkxk8rsn
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
zdgvcrpnz7tjumw7
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
737b02vaf07d
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.4
696thujpsa5inebb
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
pi4v7u rqbjgiye
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.5
w1tco 0t02c663mfc9
16 Sep 20
IPO registration (amended)
8:00pm